Registration Dossier

Administrative data

Description of key information

No repeated dose toxicity studies are available. The basis for possible read-across from organophosphonates with existing reliable studies is under review. A 90-day oral study, according to OECD 408, is therefore proposed (only in the event that no read-across from existing available reliable studies is possible). It is proposed to perform the study with the registered substance, HMDTMP (4-7K) (Potassium salts of {hexane-1,6-diylbis[nitrilobis(methylene)]}tetrakisphosphonic acid (4-7:1); EC 701-184-1).

Key value for chemical safety assessment

Repeated dose toxicity: via oral route - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: inhalation - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: inhalation - local effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: dermal - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: dermal - local effects

Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

No repeated dose toxicity studies are available and there are no suitable read-across data. A 90-day oral study, according to OECD 408, is therefore proposed.

Justification for classification or non-classification

In the absence of data, the substance is not classified for specific target organ toxicity following repeated exposures according to Regulation (EC) No 1272/2008.